Darigabat

DRUG3 trials

Sponsors

Cerevel Therapeutics, LLC, AbbVie

Conditions

HealthyHealthy ParticipantsPanic Disorder

Phase 1

Relative Bioavailability and Food Effect Following Single Oral Dose of Darigabat Tablet Formulations in Healthy Participants

CompletedNCT05123079

Cerevel Therapeutics, LLCHealthy

Start: 2021-11-02End: 2021-12-07Updated: 2022-01-21

Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants

CompletedNCT05824143

Cerevel Therapeutics, LLCHealthy Participants

Start: 2023-04-17End: 2023-07-07Updated: 2023-08-03

Phase 2

A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder

TerminatedNCT05941442

AbbViePanic Disorder

Start: 2023-07-31End: 2025-03-31Updated: 2026-05-07